(OMCL) Omnicell - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 2.020m USD | Total Return: 46.2% in 12m
Avg Turnover: 19.9M
EPS Trend: -18.2%
Qual. Beats: 1
Rev. Trend: 13.0%
Qual. Beats: 0
Warnings
P/E ratio 100.9
Tailwinds
Idiosyncratic Leader, Confidence
Omnicell, Inc. (OMCL) develops and provides automated medication management systems and adherence tools for healthcare institutions and pharmacies. Its product suite includes the Titan XT automated dispensing system, central pharmacy robotics, and IV compounding services designed to streamline clinical workflows. The company transitioned from a hardware-focused model to a broader portfolio including the OmniSphere cloud platform and the EnlivenHealth digital suite for retail pharmacy optimization.
The health care technology sector is characterized by high switching costs due to the deep integration of hardware and software into hospital infrastructure. Omnicell operates primarily through a recurring revenue model, utilizing long-term service contracts and consumable medication packaging systems to maintain customer retention. Examining the historical valuation trends on ValueRay can offer further insight into the companys market positioning. Founded in 1992 and headquartered in Fort Worth, Texas, the firm maintains operations across the United States and international markets.
- Hospital capital expenditure budgets dictate automated dispensing system sales volume
- Transition to recurring subscription revenue models impacts short-term margin profiles
- Health system labor shortages drive demand for pharmacy automation technology
- Specialty pharmacy services expansion diversifies revenue beyond traditional hardware sales
- Regulatory compliance requirements for controlled substance tracking fuel software adoption
| Net Income: 20.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.16 > 1.0 |
| NWC/Revenue: 18.28% < 20% (prev 20.44%; Δ -2.16% < -1%) |
| CFO/TA 0.08 > 3% & CFO 155.9m > Net Income 20.4m |
| Net Debt (-54.5m) to EBITDA (118.0m): -0.46 < 3 |
| Current Ratio: 1.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.9m) vs 12m ago -1.40% < -2% |
| Gross Margin: 43.50% > 18% (prev 0.43%; Δ 4.31k% > 0.5%) |
| Asset Turnover: 58.96% > 50% (prev 52.79%; Δ 6.17% > 0%) |
| Interest Coverage Ratio: 9.58 > 6 (EBITDA TTM 118.0m / Interest Expense TTM 3.61m) |
| A: 0.11 (Total Current Assets 706.9m - Total Current Liabilities 483.0m) / Total Assets 2.00b |
| B: 0.20 (Retained Earnings 396.3m / Total Assets 2.00b) |
| C: 0.02 (EBIT TTM 34.6m / Avg Total Assets 2.08b) |
| D: 0.52 (Book Value of Equity 385.7m / Total Liabilities 747.5m) |
| Altman-Z'' = 2.03 = BBB |
| DSRI: 0.97 (Receivables 264.2m/251.6m, Revenue 1.23b/1.14b) |
| GMI: 0.99 (GM 43.50% / 43.24%) |
| AQI: 1.06 (AQ_t 0.58 / AQ_t-1 0.54) |
| SGI: 1.08 (Revenue 1.23b / 1.14b) |
| TATA: -0.07 (NI 20.4m - CFO 155.9m) / TA 2.00b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of June 01, 2026, the stock is trading at USD 44.14 with a total of 589,157 shares traded.
Over the past week, the price has changed by +0.87%,
over one month by +6.57%,
over three months by +7.01% and
over the past year by +46.16%.
Omnicell has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy OMCL.
- StrongBuy: 3
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 61.3 | 38.9% |
P/E Trailing = 100.9318
P/E Forward = 29.4985
P/S = 1.6487
P/B = 1.6072
P/EG = 15.3973
Revenue TTM = 1.23b USD
EBIT TTM = 34.6m USD
EBITDA TTM = 118.0m USD
Long Term Debt = 167.9m USD (from longTermDebt, last quarter)
Short Term Debt = 11.6m USD (from shortTermDebt, last quarter)
Debt = 236.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 34.3m
Net Debt = -54.5m USD (calculated: Debt 236.5m - CCE 291.0m)
Enterprise Value = 1.97b USD (2.02b + Debt 236.5m - CCE 291.0m)
Interest Coverage Ratio = 9.58 (Ebit TTM 34.6m / Interest Expense TTM 3.61m)
EV/FCF = 17.58x (Enterprise Value 1.97b / FCF TTM 111.8m)
FCF Yield = 5.69% (FCF TTM 111.8m / Enterprise Value 1.97b)
FCF Margin = 9.12% (FCF TTM 111.8m / Revenue TTM 1.23b)
Net Margin = 1.67% (Net Income TTM 20.4m / Revenue TTM 1.23b)
Gross Margin = 43.50% ((Revenue TTM 1.23b - Cost of Revenue TTM 692.2m) / Revenue TTM)
Gross Margin QoQ = 45.30% (prev 41.51%)
Tobins Q-Ratio = 0.98 (Enterprise Value 1.97b / Total Assets 2.00b)
Interest Expense / Debt = 1.53% (Interest Expense 3.61m / Debt 236.5m)
Taxrate = 32.81% (5.55m / 16.9m)
NOPAT = 23.3m (EBIT 34.6m * (1 - 32.81%))
Current Ratio = 1.46 (Total Current Assets 706.9m / Total Current Liabilities 483.0m)
Debt / Equity = 0.19 (Debt 236.5m / totalStockholderEquity, last quarter 1.26b)
Debt / EBITDA = -0.46 (Net Debt -54.5m / EBITDA 118.0m)
Debt / FCF = -0.49 (Net Debt -54.5m / FCF TTM 111.8m)
Total Stockholder Equity = 1.24b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.98% (Net Income 20.4m / Total Assets 2.00b)
RoE = 1.64% (Net Income TTM 20.4m / Total Stockholder Equity 1.24b)
RoCE = 2.45% (EBIT 34.6m / Capital Employed (Equity 1.24b + L.T.Debt 167.9m))
RoIC = 1.87% (NOPAT 23.3m / Invested Capital 1.24b)
WACC = 6.25% (E(2.02b)/V(2.26b) * Re(6.86%) + D(236.5m)/V(2.26b) * Rd(1.53%) * (1-Tc(0.33)))
Discount Rate = 6.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 15.56 | Cagr: 0.44%
[DCF] Terminal Value 74.87% ; FCFF base≈113.7m ; Y1≈110.2m ; Y5≈108.9m
[DCF] Fair Price = 38.72 (EV 1.71b - Net Debt -54.5m = Equity 1.76b / Shares 45.5m; r=8.35% [WACC [floored]]; 5y FCF grow -4.10% → 2.50% )
EPS Correlation: -18.15 | EPS CAGR: -2.66% | SUE: 1.62 | # QB: 1
Revenue Correlation: 13.00 | Revenue CAGR: 0.68% | SUE: 0.74 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.47 | Chg30d=+12.98% | Revisions=+64% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.47 | Chg30d=-2.33% | Revisions=-33% | Analysts=8
EPS current Year (2026-12-31): EPS=1.94 | Chg30d=+10.35% | Revisions=+60% | GrowthEPS=+19.6% | GrowthRev=+5.3%
EPS next Year (2027-12-31): EPS=2.19 | Chg30d=+5.15% | Revisions=+27% | GrowthEPS=+13.3% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: +64%